Get the Stockscreener App
5.08
1.93%
-0.10
After Hours:
5.08
Coya Therapeutics Inc stock is traded at $5.08, with a volume of 59,938.
It is down -1.93% in the last 24 hours and up +0.79% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
See More
Previous Close:
$5.18
Open:
$5.19
24h Volume:
59,938
Relative Volume:
0.34
Market Cap:
$119.17M
Revenue:
$7.94M
Net Income/Loss:
$-21.13M
P/E Ratio:
-4.6959
EPS:
-1.0818
Net Cash Flow:
$-16.17M
1W Performance:
+3.89%
1M Performance:
+0.79%
6M Performance:
+21.10%
1Y Performance:
-4.33%
1-Day Range:
$5.02
$5.24
1-Week Range:
$4.831
$5.35
52-Week Range:
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.08 | 119.17M | 7.94M | -21.13M | -16.17M | -1.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
Coya Therapeutics stock maintained at Buy by H.C. Wainwright - Investing.com
Coya 302: A New Approach to Neurodegeneration - ALS News Today
Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302 - Streetwise Reports
Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant - Streetwise Reports
Coya Therapeutics (COYA) Stock Price, News & Analysis - MarketBeat
Coya Therapeutics Hits Enrollment Milestone with 100 Patients in Phase 2/3 ALSTARS ALS Trial - Kalkine Media
Trial of potential ALS treatment approaches full enrollment - ALS News Today
Form 8K Coya Therapeutics Inc For: 15 September By Investing.com - Investing.com Nigeria
Coya Therapeutics Price Target Maintained With a $16.00/Share by BTIG - Moomoo
Coya Therapeutics Advances COYA 302 ALS Phase 2/3 Trial - TipRanks
Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
Coya Therapeutics, Inc. Common Stock (NASDAQ: COYA) Stock Price, News & Analysis - kalkine.ca
Coya Therapeutics (COYA) Rises Modestly as Shares Hold Above $4.41 SupportMomentum Surge Alerts - dars.gov.et
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation - BioSpace
$32 Million Exosome Therapy Market Assessment 2026: Set to Experience Massive Growth, Reaching $1.4 Billion by 2040 - GlobeNewswire Inc.
COYA: Treg-based combination therapies show promise in ALS and FTD, with key data expected in 2027 - TradingView
Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish - Streetwise Reports
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Is This Biopharmaceutical Co. Developing ALS Drug a Buy? - Streetwise Reports
H.C. Wainwright reiterates Coya Therapeutics stock rating at buy By Investing.com - Investing.com UK
Coya (COYA) Outlook: Records a 0.21% Increase to $4.87 at the Close; Next Test: Traders Can Monitor the $4.63-$5.11 Range at the CloseDouble Bottom - careplusvn.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
COYA|Coya Therapeutics Inc|Price:4.790|Chg%:+0.120 - TradingKey
Coya Therapeutics (COYA) Holds Ground at $4.67 as Consolidation ContinuesOBV Divergence - vinanet.vn
Experimental ALS treatment being tested in Philadelphia: "There's potential here for a home run" - CBS News
Coya Therapeutics (COYA) Edges Up 0.85% to $4.73, Holding Support Amid ConsolidationGEX Level - vinanet.vn
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss Offers a Favorable SurpriseNext Quarter Guidance - vinanet.vn
COYA Pulls Back to $4.69: Coya Therapeutics Approaches Critical Support LevelHigh Dividend Factor - vinanet.vn
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Form 8K Coya Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Coya Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases - Bitget
Coya Therapeutics reports Q2 2026 net loss $6.64M, cash $43.2M; ALSTARS Phase 2 enrollment on track - TradingView
Coya Therapeutics Q2 net loss widens as R&D costs rise - TradingView
Coya Therapeutics Reports Q2 Net Loss of $6.6 Million - Quiver Quantitative
Coya Therapeutics (NASDAQ: COYA) details Q2 2026 results, ALS Fast Track and cash runway - Stock Titan
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics (NASDAQ:COYA): What Could Today’s Update Reveal About Clinical Execution And Funding Priorities? - Kalkine Media
COYA Q1 2026 Earnings: 24.1% EPS Beat Narrows Loss, Shares Rise 1.72%Special Dividend Alert - dars.gov.et
IMDX Stock Price and Chart — NASDAQ:IMDX - tradingview.com
Coya Therapeutics (NASDAQ: COYA) names Mark Pavao to its Audit Committee - Stock Titan
Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026 - marketscreener.com
Coya Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coya Therapeutics (COYA) Rallies 3.71% as Shares Press Toward Key $5 LevelFear Greed Index - careplusvn.com
Treg Therapy Market - Future Market Insights
Coya Therapeutics (COYA) Expected to Release Earnings on Tuesday - MarketBeat
Avoiding Lag: Real-Time Signals in (COYA) Movement - Stock Traders Daily
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):